STOCK TITAN

Nurix Therapeutics, Inc. - $NRIX STOCK NEWS

Welcome to our dedicated page for Nurix Therapeutics news (Ticker: $NRIX), a resource for investors and traders seeking the latest updates and insights on Nurix Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Nurix Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Nurix Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.79%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.62%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.25%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.43%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.08%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.4%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.79%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.87%
Tags
none
Nurix Therapeutics, Inc.

Nasdaq:NRIX

NRIX Rankings

NRIX Stock Data

780.44M
37.68M
2.65%
97.95%
14.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN FRANCISCO

About NRIX

nurix is a science-focused company that is committed to bringing novel, first-in-class therapies to patients. nurix is a leader in discovering a new class of drugs that work by modulating e3 ubiquitin ligases within the ubiquitin proteasome system (ups). the ups is a regulatory network that controls protein stabilization and degradation – a function vital to the healthy life of a cell – offering therapeutic opportunities in multiple disease areas. nurix’s scientific team has established an innovative drug discovery platform to identify selective inhibitors or activators of the ups, enabling the development of novel therapeutics that can restore normal cellular homeostasis. nurix was founded by internationally recognized experts in the ups field and received its initial funding from leading life science investors, third rock ventures and the column group. in 2015, nurix entered into a multi-year strategic collaboration with celgene to discover and develop next-generation therapies targe